Enzo Biochem (NYSE:ENZ) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Enzo Biochem (NYSE:ENZ) in a report released on Monday. The brokerage set a “hold” rating on the medical research company’s stock.

Enzo Biochem Price Performance

NYSE:ENZ opened at $0.58 on Monday. The stock has a 50 day simple moving average of $0.78 and a 200 day simple moving average of $1.00. Enzo Biochem has a 1-year low of $0.57 and a 1-year high of $1.40.

Enzo Biochem (NYSE:ENZ) last posted its earnings results on Monday, December 16th. The medical research company reported ($0.05) earnings per share for the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Enzo Biochem stock. BBR Partners LLC acquired a new position in shares of Enzo Biochem, Inc. (NYSE:ENZ) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 100,000 shares of the medical research company’s stock, valued at approximately $112,000. BBR Partners LLC owned 0.19% of Enzo Biochem as of its most recent SEC filing. Institutional investors and hedge funds own 36.90% of the company’s stock.

About Enzo Biochem

Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.